Hanmi Pharm FY 2025 Annual ReportBeta
Hanmi Pharm annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 20, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Hanmi Pharm FY 2025 Annual Report Analysis
Business Overview
- • Pharmaceutical segment revenue KRW 1.15T led by Rosuzet and Amozaltan; exports from Hanmi Precision Chemistry to 40+ countries
- • New product launch: Mayaping (Amozaltan) in Beijing Hanmi China in 2022 fueling overseas growth
Management Discussion & Analysis
- • Total consolidated revenue KRW 1.5475T (+3.5% YoY), operating profit KRW 258B (+19.2%), net income KRW 187.1B (+33.3%)
- • Pharmaceutical segment revenue KRW 1.1466T (+2.9%) driven by Rosuzet’s 8.4% growth to KRW 227.9B in prescription sales and increased clinical supply and royalties
Risk Factors
- • KRW 15B pre-tax impact from 10% KRW appreciation/depreciation on foreign currency exposure, up from KRW 12.2B prior year
- • KRW 1.17B earnings decrease from 1% interest rate increase on financial assets/liabilities, down from KRW 2.08B prior year
Hanmi Pharm FY 2025 Key Financial MetricsDART
Total Assets
KRW 2.14T
▲ +5.8% YoY
Operating Cash Flow
KRW 173.1B
▼ -10.6% YoY
CapEx
KRW 43.0B
▲ +9.6% YoY
Source: KIFRS consolidated financial data from Hanmi Pharm annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding